Telmisartan
- Generic Name
- Telmisartan
- Brand Names
- Actelsar Hct, Micardis, Micardis-hct, Pritor, Twynsta, Tolura, Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG), Telmisartan Teva Pharma, Telmisartan Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C33H30N4O2
- CAS Number
- 144701-48-4
- Unique Ingredient Identifier
- U5SYW473RQ
- Background
Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arter...
- Indication
Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).
- Associated Conditions
- Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hypertension
- Associated Therapies
- -
Comparison of Effects of Telmisartan and Valsartan on Neointima Volume in Diabetes
- Conditions
- Interventions
- First Posted Date
- 2008-01-24
- Last Posted Date
- 2015-09-03
- Lead Sponsor
- Korea University Anam Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT00599885
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients
- Conditions
- Interventions
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2010-07-15
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 56
- Registration Number
- NCT00560430
- Locations
- 🇩🇪
Center for Cardiovascular Research, University Berlin, Berlin, Germany
🇩🇪Med. Dept. 2, University Munich, Munich, Germany
Effect of the Known Antihypertensive Drug Telmisartan on Red Blood Cells and Circulation in the Smallest Blood Vessels
- Conditions
- Interventions
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2009-01-29
- Lead Sponsor
- RWTH Aachen University
- Target Recruit Count
- 40
- Registration Number
- NCT00559286
- Locations
- 🇩🇪
University Hospital, Aachen, NRW, Germany
Filtered Trial for Telmisartan 40mg Non-responder
- Conditions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2014-01-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 314
- Registration Number
- NCT00550953
- Locations
- 🇯🇵
1235.14.003 Boehringer Ingelheim Investigational Site, Musashino, Tokyo, Japan
🇯🇵1235.14.002 Boehringer Ingelheim Investigational Site, Chofu, Tokyo, Japan
🇯🇵1235.14.004 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan
A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Third Military Medical University
- Target Recruit Count
- 360
- Registration Number
- NCT00538486
- Locations
- 🇨🇳
The third hospital affiliated to the Third Military Medical University, Chongqing, China
Telmisartan in Haemodialysis Patients With Chronic Heart Failure
- Conditions
- First Posted Date
- 2007-06-25
- Last Posted Date
- 2008-10-17
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Target Recruit Count
- 351
- Registration Number
- NCT00490958
- Locations
- 🇮🇹
Chair of Cardiology Second University of Naples, Naples, Italy
Telmisartan and Renal Perfusion in Patients With Metabolic Syndrome
- Conditions
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2012-07-10
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 30
- Registration Number
- NCT00452192
- Locations
- 🇩🇪
Clinical Research Center, Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany
Combination of Telmisartan and Simvastatin in the Treatment of Hypertension and Hypercholesterolemia
- Conditions
- First Posted Date
- 2006-04-20
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1695
- Registration Number
- NCT00316095
- Locations
- 🇫🇷
ALTI, Angers, France
🇰🇷Hallym University Sacred Heart Hospital, Kyunggi-do, Korea, Republic of
🇳🇱Andromed Eindhoven, Eindhoven, Netherlands
Effectiveness of Candesartan and Telmisartan on Morning Hypertension in Japanese Obese Patients
- Conditions
- First Posted Date
- 2006-02-08
- Last Posted Date
- 2007-01-11
- Lead Sponsor
- Saitama Medical University
- Target Recruit Count
- 300
- Registration Number
- NCT00288717
- Locations
- 🇯🇵
Saitama Medical School Department of Renal Medicine, Saitama City, Saitama, Japan
HALT Progression of Polycystic Kidney Disease Study A
- Conditions
- Interventions
- First Posted Date
- 2006-01-30
- Last Posted Date
- 2020-04-21
- Target Recruit Count
- 558
- Registration Number
- NCT00283686
- Locations
- 🇺🇸
University of Colorado Health Sciences Center, Aurora, Colorado, United States
🇺🇸Tufts University-New England Medical Center, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.